Results 61 to 70 of about 78,778 (305)
This study reveals that large tumors secrete more chemokine CXCL3, which recruits immunosuppressive neutrophils to the periphery, thereby impairing the activation and memory of systemic tumor‑reactive CD8+ T cells. CXCL3 antagonism restores systemic immune memory and enhances the antitumor efficacy of anti‑PD‑1 therapy, offering a potential strategy to
Ji Wang +15 more
wiley +1 more source
Background: CD38+ NK (CD3− CD16+ CD38+ CD56+) cells were increased in rheumatoid arthritis (RA), which suppressed Treg cell differentiation. This study explored how CD38+ NK cells regulated CD4+ T-cell differentiation into Treg cells in RA.
Hongxing Wang +3 more
doaj +1 more source
Anti-CD38 autoimmunity in patients with systemic lupus erythematosus. [PDF]
CD38 is a multifunctional protein possessing ADP-ribosyl cyclase activity responsible for both the synthesis and the degradation of several Ca(2+)-mobilizing second messengers. In mammals, CD38 also functions as a receptor.
Rosal-Vela, Antonio +13 more
core
This study generates the single‐cell atlas of pathogenic B‐cell subset Bc‐5 in ITP. It identifies RUNX3 as a key survival regulator and uncovers sphingolipid‐driven metabolic reprogramming, validating UGCG inhibition as a therapeutic candidate and building a valuable resource for ITP mechanistic and therapeutic exploration.
Dongmei Luo +10 more
wiley +1 more source
Catalysis-based inhibitors of the calcium signaling function of CD38
CD38 is a signaling enzyme responsible for catalyzing the synthesis of cyclic ADP ribose (cADPR) and nicotinic acid adenine dinucleotide phosphate; both are universal Ca(2+) messenger molecules.
Hao, Q +19 more
core +1 more source
Upon cigarette smoke exposure(CSE), LDHA expression is increased in lung macrophages, promoting the conversion of pyruvate to lactate and elevating the lactylation level of SP1 at the K694 site. This, in turn, enhances SP1 enrichment at the TREM1 promoter, increases TREM1 expression, promoted M1 macrophage polarization, and triggers the secretion of ...
Ling Lin +5 more
wiley +1 more source
Combining CD38 antibody with CD47 blockade is a promising strategy for treating hematologic malignancies expressing CD38 [PDF]
BackgroundCD38 and CD47 are expressed in many hematologic malignancies, including multiple myeloma (MM), B-cell non-Hodgkin lymphoma (NHL), B-cell acute lymphoblastic leukemia (ALL), and B-cell chronic lymphocytic leukemia (CLL).
Chunmei Yang +18 more
core +1 more source
NK cells and CD38: Implication for (Immuno)Therapy in Plasma Cell Dyscrasias
Immunotherapy represents a promising new avenue for the treatment of multiple myeloma (MM) patients, particularly with the availability of Monoclonal Antibodies (mAbs) as anti-CD38 Daratumumab and Isatuximab and anti-SLAM-F7 Elotuzumab.
Renato Zambello +4 more
doaj +1 more source
Bioengineered stroma‐camouflaged nanovesicles (AM@UIO‐BMS/DOX) convert the immunosuppressive tumor niche into an immunoresponsive milieu by disrupting the IDO1/CD276 circuit. Anti‐CD276 membrane camouflage guides tumor accumulation and deep penetration, enabling controlled co‐delivery of DOX and the IDO1 inhibitor BMS‐986205.
Ziqi Zhang +11 more
wiley +1 more source
HADHA K406 lactylation fuels fatty acid β‐oxidation and HMGCR‐dependent cholesterol biosynthesis, fostering immunosuppressive MDSCs and exhausted CD8+ T cells in gastric cancer. Loss of this modification blocks cholesterol production, remodels the tumor microenvironment, and tumor growth is suppressed via combined inhibition of HMGCR and LDHA ...
Maoxiao Feng +10 more
wiley +1 more source

